한글목차

세계 바이러스 벡터 제조 시장의 미래는 제약 및 바이오의약품 시장과 연구기관 시장에 기회가 있어 유망한 것으로 평가되고 있습니다. 세계 바이러스 벡터 제조 시장은 2025년부터 2031년까지 18.7%의 CAGR로 2031년까지 약 36억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 바이러스 벡터를 이용한 치료에 대한 수요 증가, 바이러스 벡터 제조에 대한 투자 증가, 바이러스 벡터 제조의 기술 발전입니다.

• Lucintel의 예측에 따르면, 용도별로는 암, 희귀질환, 유전성 질환 등 다양한 질환의 치료에 대한 세포-유전자 치료에 대한 수요가 증가함에 따라 예측 기간 동안 세포 및 유전자 치료가 가장 높은 성장세를 보일 것으로 예상했습니다.
• 최종 사용 산업별로는 제약 및 바이오 제약 기업이 암, 희귀질환, 감염성 질환을 포함한 광범위한 질병에 대한 바이러스 벡터 기반 치료제를 개발 및 상용화함에 따라 제약 및 바이오 의약품이 가장 큰 부문이 될 것으로 예상됩니다.
• 지역별로는 북미의 제약 및 생명공학 산업에서 바이러스 벡터 기반 치료제에 대한 수요가 증가함에 따라 북미가 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.

바이러스 벡터 제조 시장의 전략적 성장 기회

바이러스 벡터 제조 시장은 주요 응용 분야에서 몇 가지 전략적 기회로 인해 크게 성장하고 있습니다. 이러한 성장은 기술 발전과 유전자 치료에 대한 수요 증가에 의해 주도되고 있으며, 치료 용도의 지평이 넓어지고 있습니다. 본 보고서에서는 성장 기회가 있는 5가지 주요 분야를 소개하고 바이러스 벡터 제조 시장에 미치는 영향을 개괄적으로 살펴봅니다.

• 백신 개발 : 바이러스 벡터 기술을 이용한 백신 개발이 빠르게 확대되고 있습니다. 감염성 질환 및 신종 병원체에 대한 백신은 바이러스 벡터를 사용하여 개발되고 있으며, COVID-19 백신에 바이러스 벡터를 사용하는 것은 백신 개발의 잠재력을 입증하고 있습니다. 제조업체는 벡터 기술을 강화하고 생산 규모를 확대하여 감염, 암 및 기타 건강 상태를 대상으로 하는 새롭고 개선된 백신을 생산할 수 있는 기회를 가질 수 있습니다.
• 맞춤형 의료 : 유전자 기반 맞춤형 의료는 바이러스 벡터 제조에 새로운 시장 틈새를 제공합니다. 유전자 편집 및 표적 유전자 도입과 같은 맞춤형 치료에는 바이러스 벡터가 필요합니다. 맞춤의료가 보편화됨에 따라 특정 환자의 요구에 맞는 맞춤형 바이러스 벡터에 대한 수요가 증가하고 있습니다. 이러한 추세는 유연한 생산 솔루션을 제공하고 혁신적인 벡터 시스템을 개발함으로써 활용할 수 있습니다.
• 새로운 시장 : 바이러스 벡터 제조는 아시아태평양 및 라틴아메리카와 같은 신흥 시장에 새로운 성장의 길을 열어주고 있습니다. 이들 지역에서는 바이오 제약 분야가 발전하고 헬스케어에 대한 투자가 증가함에 따라 바이러스 벡터에 대한 수요가 증가하고 있습니다. 더 높은 성장률로 확장하고자 하는 기업들은 유전자 및 세포 치료제에 대한 수요 증가에 대응하기 위해 현지 파트너를 찾고, 신흥 시장의 상황을 활용하고, 현지에 생산 시설을 설립하고, 규제 상황을 효과적으로 조정해야 합니다.

바이러스 벡터 제조 시장은 유전자 및 세포 치료제, 백신 개발, 맞춤형 의료, 신흥국 시장 등 전략적 성장 기회를 통해 성장하고 있습니다. 이러한 핵심 분야에 집중함으로써 생명을 개선하는 의약품에 대한 수요 증가에 대응하는 동시에 시장에서의 입지를 강화할 수 있습니다. 이러한 기회는 바이러스 벡터 제조의 성장을 촉진하고 미래의 방향성을 계속 형성할 것으로 보입니다.

바이러스 벡터 제조 시장의 촉진요인 및 과제

몇 가지 힘과 과제가 바이러스 벡터 제조 시장의 역학을 정의하고 있습니다. 주요 성장 촉진요인으로는 기술 혁신, 더 나은 치료 기술에 대한 수요 증가, 재정 투자 확대 등을 들 수 있습니다. 반면, 이 산업은 높은 제조 비용, 규제 복잡성, 기술적 복잡성 등의 단점에 직면해 있습니다. 이 시장의 기업들에게 이러한 요인을 이해하는 것은 잠재적 과제를 극복하기 위한 최적의 전략을 결정하는 데 매우 중요합니다.

바이러스 벡터 제조 시장을 이끄는 요인은 다음과 같습니다:

• 기술 발전 : 기술 발전은 바이러스 벡터 제조 시장의 성장을 촉진하는 큰 힘이 되고 있습니다. 자동화, 일회용 기술, 고급 분석 기능 등의 기술 혁신으로 제조 시 효율성, 확장성, 품질이 향상되고 있습니다. 이러한 기술 개선을 통해 생산자는 단위 시간당 생산량을 확보하면서 비용을 절감하고, 바이러스 벡터의 수요 증가에 대응할 수 있게 되었습니다. 기술이 더욱 발전하면 생산능력을 향상시키고 새로운 치료법 개발 활동을 촉진할 수 있는 기회를 제공할 것입니다.
• 고급 의약품에 대한 수요 증가 : 유전자 치료 및 세포 치료에 대한 수요 증가는 시장 성장을 촉진하는 중요한 요인입니다. 임상시험에서 상업화로 전환하는 치료법의 수가 증가함에 따라 치료 유전자를 전달할 수 있는 더 나은 바이러스 벡터가 필요하게 되었습니다. 이에 따라 제조업체들은 생산능력을 확대하고 신기술에 대한 투자를 늘리고 있습니다. 바이러스 벡터 제조 분야의 추가 확대와 기술 혁신은 첨단 치료의 성장에 의해 촉진될 것입니다.
• 바이오의약품에 대한 투자 증가 : 바이러스 벡터 제조 시장의 성장은 바이오의약품 산업에 대한 투자 증가에 의해 촉진될 것입니다. 공공 및 민간의 자금 지원은 연구개발과 새로운 제조 시설의 설립을 촉진할 것입니다. 바이오의약품 인프라 및 기술에 대한 투자는 생산 규모를 확대하고 역량을 강화하기 위해 필요합니다. 투자 증가에 따라 바이러스 벡터 제조의 추가 개선이 예상되며, 이는 시장 성장으로 이어질 것으로 예상됩니다.

바이러스 벡터 제조 시장의 과제는 다음과 같습니다:

• 높은 제조 비용 : 바이러스 벡터 제조는 높은 제조 비용에 직면해 있으며, 이는 큰 도전이 되고 있습니다. 특수 장비와 고품질 원료를 필요로 하는 바이러스 벡터 제조 공정이 복잡하기 때문에 추가 비용이 발생합니다. 또한, 엄격한 규제 기준을 준수하는 것은 기업에게 경제적 부담이 될 수 있습니다. 이러한 비용 문제를 해결하기 위해서는 제조 공정의 혁신과 시장 내 수익성과 지속가능성을 보장하는 비용 효율적인 기술에 대한 투자가 필요합니다.
• 규제 허가의 어려움 : 바이러스 벡터 제조 산업은 규제와 관련된 어려움에 직면해 있습니다. 제품의 안전성과 유효성은 복잡하고 변화하는 규제를 준수함으로써 보장되어야 합니다. 우수 제조 기준(GMP) 가이드라인을 준수하고 규제 당국의 승인을 받는 데는 많은 비용이 소요됩니다. 이러한 문제를 극복하기 위해 제조업체는 변화하는 규제에 대응할 수 있는 품질 관리 조치에 많은 투자를 해야 합니다. 컴플라이언스를 효율적으로 관리하는 것은 시장 접근성을 유지하고 바이러스 벡터 기반 치료제의 성공적인 상용화를 위해 필수적입니다.

결론적으로, 시장 역학은 바이러스 벡터 제조 시장이 직면한 촉진요인과 과제에 의해 형성됩니다. 시장의 성장은 기술 발전, 첨단 치료법에 대한 수요 증가, 투자 증가에 의해 촉진되는 반면, 제조 비용 상승과 규제 장벽에 대한 도전은 여전히 존재합니다. 기술 혁신과 전략적 투자를 통해 이러한 과제를 극복하는 것이 시장의 지속적인 성공과 확장을 위해 필수적입니다.

목차

제1장 주요 요약

제2장 세계의 바이러스 벡터 제조 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계 성장 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 바이러스 벡터 제조 시장 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 바이러스 벡터 제조 시장 : 종류별
  • 아데노바이러스
  • 레트로바이러스
  • 아데노 부속 바이러스
  • 렌티바이러스
  • 플라스미드 DNA
  • 기타
• 세계의 바이러스 벡터 제조 시장 : 워크플로우별
  • 업스트림 제조
  • 다운스트림 제조
• 세계의 바이러스 벡터 제조 시장 : 용도별
  • 세포 및 유전자 치료
  • 백신학
  • 연구, 기타 용도
• 세계의 바이러스 벡터 제조 시장 : 최종 용도별
  • 제약·바이오의약품
  • 연구기관
  • 기타

제4장 지역별 시장 동향과 예측 분석(2019-2031년)

• 세계의 바이러스 벡터 제조 시장 : 지역별
• 북미의 바이러스 벡터 제조 시장
• 유럽의 바이러스 벡터 제조 시장
• 아시아태평양의 바이러스 벡터 제조 시장
• 기타 지역의 바이러스 벡터 제조 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 바이러스 벡터 제조 시장 성장 기회 : 종류별
  • 세계의 바이러스 벡터 제조 시장 성장 기회 : 워크플로우별
  • 세계의 바이러스 벡터 제조 시장 성장 기회 : 용도별
  • 세계의 바이러스 벡터 제조 시장 성장 기회 : 최종 용도별
  • 세계의 바이러스 벡터 제조 시장 성장 기회 : 지역별
• 세계의 바이러스 벡터 제조 시장 최신 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 바이러스 벡터 제조 시장 생산능력 확대
  • 세계의 바이러스 벡터 제조 시장 기업 인수합병(M&A), 합작투자
  • 인증과 라이선싱

제7장 주요 기업 개요

• Merck
• Lonza
• FUJIFILM Diosynth Biotechnologies
• Thermo Fisher Scientific
• Cobra Biologics
• Catalent
• Wuxi Biologics
• Takara Bio
• Waisman Biomanufacturing
• Genezen laboratories

영문목차

The future of the global viral vector manufacturing market looks promising with opportunities in the pharmaceutical & biopharmaceutical and research institutes markets. The global viral vector manufacturing market is expected to reach an estimated $3.6 billion by 2031 with a CAGR of 18.7% from 2025 to 2031. The major drivers for this market are the increasing demand for viral vector-based therapies, growing investment in viral vector manufacturing, and technological advancements in viral vector manufacturing.

• Lucintel forecasts that, within the application category, cell and gene therapy is expected to witness the highest growth over the forecast period due to the growing demand for cell and gene therapies for the treatment of a wide range of diseases, including cancer, rare diseases, and genetic disorders.
• Within the end use industry category, pharmaceutical and biopharmaceutical will remain the largest segment because these pharmaceutical and biopharmaceutical companies are developing and commercializing viral vector-based therapies for a wide range of diseases, including cancer, rare diseases, and infectious diseases.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to increasing demand for viral vector-based therapies from the pharmaceutical and biotechnology industries in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Viral Vector Manufacturing Market

The viral vector manufacturing market is undergoing significant changes, driven by emerging trends that are reshuffling the industry. Some of these trends include progress in production technologies, increased demand for gene and cell therapies, collaboration between private firms and institutions of higher learning, growth of disposable technology platforms, and a notable emphasis on regulatory compliance. While improving productivity and scalability in viral vector manufacturing, these trends also help address issues related to cost structures, quality control, and supply chain challenges.

• Manufacturing Technologies Advancements: A key trend in the viral vector manufacturing market is advancements in manufacturing technologies. The production of viral vectors is being revolutionized by novel inventions like automated production systems, single-use bioreactors, and high-throughput screening. More effective and scalable methods are currently being made possible through these developments, which save time and costs related to production. Additionally, downstream processing and purification methods have advanced, leading to better quality and greater quantities of viral vectors. These advancements will significantly impact manufacturing efficiency as they become more popular, thus contributing to the growth of the market.
• Uneven Surge in Gene and Cell Therapies: A significant factor driving the viral vector manufacturing market's growth is the increasing demand for gene and cell therapies. The requirement for high-quality viral vectors has been driven by the transition of more gene and cell therapies from clinical trials to commercialization. This has prompted manufacturers to expand their production capacity and develop new facilities to cater to the increasing market size. Furthermore, recent successful gene therapies have attracted more investor attention to the industry, leading to increased funding for viral vector manufacturing capabilities. This trend is projected to continue, thereby further expanding the market.
• Advocates for More Collaboration and Partnerships: A major trend in the viral vector manufacturing market is the increased collaboration among pharmaceutical companies, academic institutions, and CMOs. These associations help promote innovation and expedite the development of new viral vector generation methods. These partnerships result in more efficient production processes through the pooling of resources and expertise, as well as the development of new therapies. This is also giving rise to various strategic alliances aimed at expanding manufacturing capabilities while improving the availability of viral vectors. In conclusion, it can be said that increasing partnerships will lead to major market progressions.
• Emphasis on Regulatory Compliance: Another significant trend in viral vector manufacturing is a strong emphasis on regulatory compliance. As the sector expands, manufacturers are increasingly focused on strict regulatory norms that guarantee the safety and effectiveness of their products. These include adherence to Good Manufacturing Practices (GMP) as well as compliance with regional and global regulations. Consequently, a focus on regulatory compliance has led manufacturers to adopt quality control systems, advanced analytics, and efficient documentation procedures. As regulatory demands evolve, keeping pace with them will be vital for drug firms to thrive in the competitive viral vector industry.

The landscape of viral vector manufacturing is changing due to technological advancements, a rise in demand for gene therapies, increased collaborative activities, greater use of single-use technologies, and the importance of regulatory compliance. Innovation propelled by these trends will enhance production efficiency and expand market reach. As such, it is anticipated that this sector will continue to grow while creating new avenues for viral vector manufacturing companies. To maintain momentum and ensure long-term success in the market, continued focus in these areas is crucial.

Recent Developments in the Viral Vector Manufacturing Market

Recent developments in the viral vector manufacturing market have led to significant improvements driven by the increased demand for gene and cell therapies. These developments include advancements in production technology, expansion of manufacturing capacity, and improvements in regulatory compliance procedures. Important changes are occurring with the growth of the market, which intends to concentrate on improving efficiency, scalability, and quality control processes. Such developments enhance viral vector production, yielding better outcomes for therapeutic applications needed by the industry.

• Expansion of Manufacturing Facilities: Recent expansions in manufacturing facilities are crucial for meeting the growing demand for viral vectors. Major biopharmaceutical companies are investing in new production sites and updating existing ones. These efforts aim to expand capacity, enhance scalability, and improve production efficiency. New facilities often incorporate advanced technologies such as automated systems and single-use technologies to streamline processes and ensure high-quality outputs. This development is vital to supporting the increased volume of gene and cell therapies reaching the marketplace and addressing supply chain challenges.
• Embracing Advanced Concepts: Viral vector manufacturing is evolving due to the adoption of advanced technologies. Examples include, but are not limited to, automation, AI, and high-throughput screening. The manufacturing process is simplified using automated systems, thus reducing human error and increasing output. Process optimization and quality control can be enhanced through AI and machine learning. These technologies also enable higher yields and faster production cycles that meet the rising demand for viral vectors in support of advanced therapeutic solutions.
• Novel Viral Vectors Development: The emergence of new viral vectors is expanding gene therapy options. This is achieved by creating brand-new viral vector systems with superior safety profiles, improved transduction efficiencies, and enhanced tissue targeting. These improvements address traditional vector limitations, including low tissue specificity or immune responses. In general, novel vectors facilitate better-targeting approaches for a variety of genetic disorders and cancers. This development thus expands the spectrum of therapeutic applications, leading to further progress in the gene therapy sector.
• Increased Emphasis on Quality and Compliance: The viral vector manufacturing market is being shaped by a heightened emphasis on quality and regulatory compliance. Manufacturers are investing in robust quality control mechanisms that enforce strict regulatory standards to ensure product safety and efficacy. This includes the adoption of Good Manufacturing Practice (GMP) guidelines and advanced analytical methods for process monitoring. Enhanced quality assurance practices help prevent contamination, ensuring that products remain consistently high-quality, which is vital for regulatory approvals and maintaining confidence in viral vector-based therapeutics.

The viral vector manufacturing market is currently experiencing significant developments such as facility expansions, new vector development, quality improvements, and the rise of partnerships, all of which are having a substantial impact on the industry. These changes will enhance manufacturing capacity, efficiency, and quality, which are critical factors for meeting the growing needs for gene and cell therapies. With further development expected as the market continues to evolve, these advances will be instrumental in driving growth and innovation, thereby positioning viral vector production for continued prosperity.

Strategic Growth Opportunities for Viral Vector Manufacturing Market

The viral vector manufacturing market is witnessing substantial growth due to several strategic opportunities across key applications. This progression has been driven by increased technological advancements and demand for gene therapies, while the therapeutic application horizon has prospered. This discussion presents five major areas where there are growth opportunities, outlining their impacts on the viral vector manufacturing market.

• Vaccine Development: * Within the marketplace, vaccine development through viral vector technology has emerged as a rapidly expanding field. Vaccines for infectious diseases and emerging pathogens are being developed using viral vectors. The use of viral vectors in COVID-19 vaccines has demonstrated their potential in vaccine development. Manufacturers have an opportunity to enhance vector technologies and scale up production to help produce new and improved vaccines targeting infectious diseases, cancer, and other health conditions.
• Personalized Medicine: Genetic-based personalized medicine offers a new market niche for viral vector manufacturing. Personalized therapies, such as gene editing or targeted gene delivery, require viral vectors. As individualized medicine becomes more common, there is a growing demand for customized viral vectors that address particular patient needs. This trend can be exploited by offering flexible production solutions and developing innovative vector systems.
• New Markets: Viral vector manufacturing is opening up new avenues of growth in emerging markets like Asia-Pacific and Latin America. The demand for viral vectors is rising as these regions develop their biopharmaceutical sectors and invest more in healthcare. This desire to expand at a higher rate has compelled businesses to seek local partners, take advantage of the emerging market landscape, establish regional production facilities, and navigate regulatory frameworks effectively to meet the increasing demand for gene and cell therapies.

Industry expansion has been driven by strategic growth opportunities in the viral vector manufacturing market, such as gene and cell therapy applications, vaccine development, personalized medicine, and emerging markets. Market presence can be improved by focusing on these important areas while responding to the increased demand for life-improving medications. These opportunities will continue to drive growth in viral vector manufacturing, shaping its future course.

Viral Vector Manufacturing Market Driver and Challenges

Several forces and challenges define the dynamics of the viral vector manufacturing market. Some of the primary growth drivers include innovation, increasing demand for better treatment techniques, and greater financial investments. Conversely, the industry faces drawbacks such as high production costs, regulatory complications, and technical intricacies. For players in this market, understanding these factors is crucial for determining the best strategies to overcome potential challenges.

The factors driving the viral vector manufacturing market include:

• Technological Advancements: Technological advancements have been a major force driving growth in the viral vector manufacturing market. Innovations such as automation, single-use technologies, and advanced analytical capabilities have improved efficiency, scalability, and quality during production. These technological improvements reduce costs while ensuring greater output per unit of time, enabling producers to meet the rising demand for viral vectors. As technology advances further, it will also offer opportunities for enhancing production capacity and facilitating new therapeutic development activities.
• Growing Demand for More Advanced Drugs: The increasing demand for gene and cell therapies is a key factor driving market growth. The rising number of therapies transitioning from clinical trials to commercialization requires better viral vectors to deliver therapeutic genes. Consequently, this prompts manufacturers to expand their production capacities and invest in new technologies. Further expansion and innovation in the viral vector manufacturing sector will be driven by the growth of advanced therapies.
• Increasing Investment in Biopharmaceuticals: The growth of the viral vector manufacturing market is fueled by increased investment in the biopharmaceutical industry. Funding from public and private sectors facilitates research and development as well as the establishment of new manufacturing facilities. Investments in biopharmaceutical infrastructure and technology are necessary to scale up production and enhance capabilities. With rising levels of investment, further improvements in viral vector manufacturing are expected, leading to market growth.

Challenges in the viral vector manufacturing market include:

• High Cost of Production: Viral vector manufacturing faces high production costs, which is a major challenge. Additional costs arise from the complexities of the viral vector production process, which requires specialized equipment and high-quality raw materials. Furthermore, compliance with strict regulatory standards adds a financial burden on companies. Addressing these cost challenges necessitates innovations in manufacturing processes and investments in cost-effective technologies to ensure profitability and sustainability within the market.
• Difficulties in Regulatory Clearance: The viral vector manufacturing industry faces challenges related to regulation. The safety and efficacy of products must be ensured through adherence to complex and ever-changing regulations. Costs are incurred when complying with Good Manufacturing Practice (GMP) guidelines and obtaining regulatory approvals. To overcome these challenges, manufacturers should invest heavily in quality control measures that can withstand regulatory changes. Efficient management of compliance is critical for maintaining access to markets and successfully commercializing therapies based on viral vectors.

In conclusion, market dynamics are shaped by the drivers and challenges facing the viral vector manufacturing market. Market growth is propelled by technological advancements, rising demand for advanced therapies, and increased investments, while challenges persist related to high production costs and regulatory hurdles. Overcoming these challenges through innovation and strategic investments will be essential for the continued success and expansion of the market.

List of Viral Vector Manufacturing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies viral vector manufacturing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the viral vector manufacturing companies profiled in this report include-

• Merck
• Lonza
• Fujifilm Diosynth Biotechnologies
• Thermo Fisher Scientific
• Cobra Biologics
• Catalent
• Wuxi Biologics
• Takara Bio
• Waisman Biomanufacturing
• Genezen Laboratories

Viral Vector Manufacturing by Segment

The study includes a forecast for the global viral vector manufacturing market by type, workflow, application, end use, and region.

Viral Vector Manufacturing Market by Type [Analysis by Value from 2019 to 2031]:

• Adenovirus
• Retrovirus
• Adeno-Associated Virus
• Lentivirus
• Plasmid DNA
• Others

Viral Vector Manufacturing Market by Workflow [Analysis by Value from 2019 to 2031]:

• Upstream Manufacturing
• Downstream Manufacturing

Viral Vector Manufacturing Market by Application [Analysis by Value from 2019 to 2031]:

• Cell & Gene Therapy
• Vaccinology
• Research & Other Applications

Viral Vector Manufacturing Market by End Use [Analysis by Value from 2019 to 2031]:

• Pharmaceutical & Biopharmaceutical
• Research Institutes
• Others

Viral Vector Manufacturing Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Viral Vector Manufacturing Market

Viral vector manufacturing is a global market that is growing rapidly due to the increased demand for gene therapies, vaccines, and cell-based treatments. In these processes, viral vectors are used as agents to introduce genetic materials into the cells where they should be placed. In key economies, including the United States, China, Germany, India, and Japan, there have been considerable developments in manufacturing capabilities, regulatory approvals, and technological innovations, among others.

• United States: The growth of viral vector manufacturing in the country is attributable to the increasing usage of gene therapies and vaccines. Major biopharmaceutical companies and contract development and manufacturing organizations (CDMOs) are expanding their production facilities in response to the growing demand. New plants are being constructed, and existing ones are being retrofitted with new technologies to enhance capacity and ensure compliance with GMP standards. These actions bolster America's ability to produce scalable, high-quality viral vectors, establishing it as a global leader and a role model in manufacturing prowess.
• China: In China, the viral vector manufacturing sector is rapidly changing due to strong governmental efforts to enhance biotechnology and gene therapy sectors. The Chinese authorities have made significant investments in biopharmaceutical infrastructure, particularly in viral vector manufacturing facilities. Furthermore, provincial enterprises are adopting high-end production technologies for increased productivity and quality improvement. This collaboration between academia and industry has spurred innovation in viral vectors. Consequently, these trends position China as one of the main global players, with increasing capacity to meet both local and foreign demand for viral vectors.
• Germany: In terms of viral vector manufacturing, Germany leads in innovation while maintaining high standards of quality control and advanced manufacturing processes. German companies are investing in cutting-edge technologies such as automated production systems and single-use bioreactors, which have improved the efficiency and scalability of viral vector production. Additionally, its stringent regulatory framework ensures that manufacturing processes meet the highest quality standards, solidifying Germany's position as a major player in Europe and enhancing its global competitiveness in the biopharmaceutical sector.
• India: India is becoming a formidable force in the viral vector manufacturing market, especially in contract manufacturing. Its skilled labor force and lower production costs make it an attractive destination for outsourcing viral vector production. Indian companies are increasing their manufacturing capacity by investing in new plants and adopting cutting-edge technologies to meet the growing global demand for viral vectors. Moreover, India's regulatory environment is being aligned with international standards, further enhancing its appeal as a leading center for viral vector manufacturing. Thus, India is now positioned as a major supplier on the global market stage.
• Japan: Japan's viral vector manufacturing market is characterized by a blend of emerging technologies and substantial research and development focus. AI and automation are leading ventures for innovation in this field, being undertaken by Japanese companies to enhance accuracy and efficiency in viral vector manufacturing. Furthermore, Japan has a mature regulatory framework that facilitates the rapid development and commercialization of novel therapies. These aspects position Japan as a major player in the viral vector market, leading its competitors in technology advancement and ensuring its competitiveness in the global market.

Features of the Global Viral Vector Manufacturing Market

Market Size Estimates: Viral vector manufacturing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Viral vector manufacturing market size by various segments, such as by type, workflow, application, end use, and region in terms of value ($B).

Regional Analysis: Viral vector manufacturing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, workflows, applications, end uses, and regions for the viral vector manufacturing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the viral vector manufacturing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the viral vector manufacturing market by type (adenovirus, retrovirus, adeno-associated virus, lentivirus, plasmid DNA, and others), workflow (upstream manufacturing and downstream manufacturing), application (cell & gene therapy, vaccinology, and research & other applications), end use (pharmaceutical & biopharmaceutical, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Viral Vector Manufacturing Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Viral Vector Manufacturing Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Viral Vector Manufacturing Market by Type
  • 3.3.1: Adenovirus
  • 3.3.2: Retrovirus
  • 3.3.3: Adeno-Associated Virus
  • 3.3.4: Lentivirus
  • 3.3.5: Plasmid DNA
  • 3.3.6: Others
• 3.4: Global Viral Vector Manufacturing Market by Workflow
  • 3.4.1: Upstream Manufacturing
  • 3.4.2: Downstream Manufacturing
• 3.5: Global Viral Vector Manufacturing Market by Application
  • 3.5.1: Cell & Gene Therapy
  • 3.5.2: Vaccinology
  • 3.5.3: Research & Other Applications
• 3.6: Global Viral Vector Manufacturing Market by End Use
  • 3.6.1: Pharmaceutical & Biopharmaceutical
  • 3.6.2: Research Institutes
  • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Viral Vector Manufacturing Market by Region
• 4.2: North American Viral Vector Manufacturing Market
  • 4.2.1: North American Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
  • 4.2.2: North American Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others
• 4.3: European Viral Vector Manufacturing Market
  • 4.3.1: European Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
  • 4.3.2: European Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others
• 4.4: APAC Viral Vector Manufacturing Market
  • 4.4.1: APAC Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
  • 4.4.2: APAC Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others
• 4.5: ROW Viral Vector Manufacturing Market
  • 4.5.1: ROW Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
  • 4.5.2: ROW Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Viral Vector Manufacturing Market by Type
  • 6.1.2: Growth Opportunities for the Global Viral Vector Manufacturing Market by Workflow
  • 6.1.3: Growth Opportunities for the Global Viral Vector Manufacturing Market by Application
  • 6.1.4: Growth Opportunities for the Global Viral Vector Manufacturing Market by End Use
  • 6.1.5: Growth Opportunities for the Global Viral Vector Manufacturing Market by Region
• 6.2: Emerging Trends in the Global Viral Vector Manufacturing Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Viral Vector Manufacturing Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Viral Vector Manufacturing Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Merck
• 7.2: Lonza
• 7.3: FUJIFILM Diosynth Biotechnologies
• 7.4: Thermo Fisher Scientific
• 7.5: Cobra Biologics
• 7.6: Catalent
• 7.7: Wuxi Biologics
• 7.8: Takara Bio
• 7.9: Waisman Biomanufacturing
• 7.10: Genezen laboratories